BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18577182)

  • 1. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.
    Graham HK; Horn M; Trafford AW
    Acta Physiol (Oxf); 2008 Sep; 194(1):3-21. PubMed ID: 18577182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW; Verma S; Weisel RD; Li RK
    Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.
    Moore L; Fan D; Basu R; Kandalam V; Kassiri Z
    Heart Fail Rev; 2012 Sep; 17(4-5):693-706. PubMed ID: 21717224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
    Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
    J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
    Wilson EM; Spinale FG
    Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
    Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
    J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG
    Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.
    Voloshenyuk TG; Gardner JD
    Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
    Vanhoutte D; Heymans S
    J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation.
    El Hajj EC; El Hajj MC; Voloshenyuk TG; Mouton AJ; Khoutorova E; Molina PE; Gilpin NW; Gardner JD
    Alcohol Clin Exp Res; 2014 Feb; 38(2):448-56. PubMed ID: 24033327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY; McTiernan CF; Feldman AM
    Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
    Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
    Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.
    Lindsey ML; Zamilpa R
    Cardiovasc Ther; 2012 Feb; 30(1):31-41. PubMed ID: 20645986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
    Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
    J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.
    Givvimani S; Kundu S; Narayanan N; Armaghan F; Qipshidze N; Pushpakumar S; Vacek TP; Tyagi SC
    Arch Physiol Biochem; 2013 May; 119(2):65-74. PubMed ID: 23398532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure.
    Frangogiannis NG
    Circ Res; 2019 Jun; 125(1):117-146. PubMed ID: 31219741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to retard ventricular remodeling in heart failure.
    Spinale FG
    Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.